Posted by Michael Wonder on 09 Sep 2025
ICER releases draft evidence report on treatments for obesity
9 September 2025 - Public comment period now open until 6 October 2025; requests to make oral comment during public meeting also being accepted.
The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of semaglutide (Wegovy) (Novo Nordisk) and tirzepatide (Zepbound) (Eli Lilly) for obesity management. The ICER is also assessing how these treatments affect additional obesity-related outcomes.
